期刊
DIABETES OBESITY & METABOLISM
卷 18, 期 -, 页码 137-143出版社
WILEY
DOI: 10.1111/dom.12721
关键词
beta-cells; stem cells; transdifferentiation; transplantation; type 1 diabetes
资金
- Juvenile Diabetes Research foundation [17-2011-16, 2-2010-567, 26-2008-639, 17-2013-426]
- INSERM AVENIR program
- INSERM
- European Research Council [StG-2011-281265]
- FMR [DRC20091217179]
- ANR/BMBF [2009 GENO 105 01/01KU0906]
- Investments for the Future LABEX SIGNALIFE [ANR-11-LABX-0028-01]
- Club Isatis
- Fondation Generale de Sante
- Foundation Schlumberger pour l'Education et la Recherche
To efficiently treat type 1 diabetes, exogenous insulin injections currently represent the main approach to counter chronic hyperglycaemia. Unfortunately, such a therapeutic approach does not allow for perfectly maintained glucose homeostasis and, in time, cardiovascular complications may arise. Therefore, seeking alternative/improved treatments has become a major health concern as an increasing proportion of type 2 diabetes patients also require insulin supplementation. Towards this goal, numerous laboratories have focused their research on beta-cell replacement therapies. Herein, we will review the current state of this research area and describe the cell sources that could potentially be used to replenish the depleted beta-cell mass in diabetic patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据